Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward.

IF 2.4 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular Translational Research Pub Date : 2025-04-09 DOI:10.1007/s12265-025-10614-1

Wenhai Wang, Dexin Xu, Jian Ding, Yinping Pan, Fang Wang, Shu Su, Xia Peng, Shitong Zhang, Wenbin Zhang

{"title":"Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward.","authors":"Wenhai Wang, Dexin Xu, Jian Ding, Yinping Pan, Fang Wang, Shu Su, Xia Peng, Shitong Zhang, Wenbin Zhang","doi":"10.1007/s12265-025-10614-1","DOIUrl":null,"url":null,"abstract":"<p><p>Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice.</p>","PeriodicalId":15224,"journal":{"name":"Journal of Cardiovascular Translational Research","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Translational Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12265-025-10614-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Myocardial infarction (MI) is a global health concern that necessitates continued advancements in diagnostic and therapeutic modalities. Nanotechnology facilitates prompt diagnosis and personalized treatment. This manuscript explicitly reviews the application of innovative methodologies for identifying cardiac biomarkers to facilitate the early diagnosis of MI and its clinical management. Nanoscale agents such as nanoparticles and nanosensors have been employed for this purpose. Technological advancements in medical imaging are revolutionizing therapeutic approaches while reducing morbidity and mortality typically associated with cardiac tissue injury. Besides all, applications of nanotechnology in therapeutics have proven extremely effective. The development of nanoparticle-based customized drug delivery systems will contribute to more effective treatments, fewer side effects, and improved therapeutic outcomes. Biomaterials and nanoscale surgical technologies may benefit patients with MI by promoting tissue regeneration and repair. This manuscript also investigates the ethical and legal limitations that could prevent seamless incorporation of nanotechnology into clinical practice.

查看原文本刊更多论文

纳米技术在心肌梗死中的创新：诊断、治疗和前进的道路。

心肌梗死（MI）是一个全球性的健康问题，需要在诊断和治疗方式上不断取得进展。纳米技术有助于及时诊断和个性化治疗。本文明确回顾了识别心脏生物标志物的创新方法的应用，以促进心肌梗死的早期诊断及其临床管理。纳米级试剂如纳米颗粒和纳米传感器已被用于这一目的。医学成像技术的进步正在彻底改变治疗方法，同时降低与心脏组织损伤相关的发病率和死亡率。此外，纳米技术在治疗方面的应用已被证明是非常有效的。基于纳米颗粒的定制给药系统的发展将有助于更有效的治疗，更少的副作用，并改善治疗结果。生物材料和纳米手术技术可以促进心肌梗死患者的组织再生和修复。这份手稿还调查了伦理和法律上的限制，可能会阻止纳米技术无缝结合到临床实践。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cardiovascular Translational Research CARDIAC & CARDIOVASCULAR SYSTEMS-MEDICINE, RESEARCH & EXPERIMENTAL

CiteScore

6.10

自引率

2.90%

发文量

148

审稿时长

6-12 weeks

期刊介绍： Journal of Cardiovascular Translational Research (JCTR) is a premier journal in cardiovascular translational research. JCTR is the journal of choice for authors seeking the broadest audience for emerging technologies, therapies and diagnostics, pre-clinical research, and first-in-man clinical trials. JCTR''s intent is to provide a forum for critical evaluation of the novel cardiovascular science, to showcase important and clinically relevant aspects of the new research, as well as to discuss the impediments that may need to be overcome during the translation to patient care.